News

Dr. Yuxin Chen Received Peptide Application Special Award

2018-07-10

From July 4th to 6th, 2018, the15th Chinese International Peptide Sympossium was hold in Shenzhen. During the sympossium, Dr. Yuxin Chen, president of ProteLight Pharma, received the  Peptide Application Special Awar for his outstanding contribution to peptide science.

 

Previous article

ProteLight Pharma Focuses on R & D of Antimicrobial Peptide New Drugs -- Declare War on “Superbugs”

Next article

ProteLigt R & D Team was named as “Innovation and Entrepreneurship Team” of Jiangsu Province in 2017

/news_detail/49.html

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-18 Suppository Has Received FDA Approval to Commence Clinical Studies.

—

2024-10-26

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-18 Suppository Has Received FDA Approval to Commence Clinical Studies.

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-3301 Oral Gel Has Been Granted FDA Approval To Commence Clinical Trials.

■

The publication of a confirmative Phase III clinical study on Peceleganan Spray (project code: PL-5), an innovative antimicrobial peptide developed by ProteLight Pharms, has been released.

■

ProteLight Pharma was selected into the list of “Top 100 Chinese Pharmaceutical Innovative Seed Enterprises in 2023”

■

Congratulations to the company for passing the ISO9001 quality management system certification

■

Antimicrobial Peptide PL-18 Suppository (First-in-class new drug) of ProteLight Pharma Received Clinical Trial Approval from CDE in China